Enhertu

News

Image of the word No in gold neon lights

NICE blocks Enhertu use after pricing talks break down

NICE and drugmakers AstraZeneca and Daiichi Sankyo have all expressed their disappointment at being unable to agree on a price for Enhertu that would allow it to be used on the NHS for peop

News

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

Two impressive studies in lung cancer and another in breast cancer made Sunday a stellar day for AstraZeneca at the ASCO congress.

News

AstraZeneca unveils plan for $1.5bn ADC plant in Singapore

AstraZeneca is backing up its considerable investment in antibody-drug conjugates (ADCs) for cancer with the construction of a $1.5 billion new facility in Singapore to ma

News

Roche gets EU okay for first HER2-low test kit

Roche has obtained a CE Mark in the EU for a companion diagnostic that can be used to identify patients with HER2-low metastatic breast cancer who may be eligible for trea

News

Enhertu gets FDA nod for tumour-agnostic HER2 cancers

The FDA has approved the use of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu for all HER2-positive solid tumours, in a first for both HER2 inhibitors a

News

Surprise Enhertu rejection follows NICE process change

NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described

NICE blocks Enhertu use after pricing talks break down

ASCO: AstraZeneca’s triple whammy in lung and breast cancer

AstraZeneca unveils plan for $1.5bn ADC plant in Singapore

Roche gets EU okay for first HER2-low test kit

Enhertu gets FDA nod for tumour-agnostic HER2 cancers

Surprise Enhertu rejection follows NICE process change

Sobi adds rare lymphoma drug with $580m Innate tie-up

Discover a new era of healthcare panel engagement: Grounded ...

Enhertu

Editor's Picks